Meningococcal disease remains a global health concern.

Meningococcal serogroup A, C, W and Y glycoconjugate vaccine with tetanus toxoid as a carrier protein (ACWY-TT) has been demonstrated to be safe and immunogenic when administered to young children from 12 months of age, older children, adolescents and adults.

When compared to meningococcal serogroup A, C, W and Y polysaccharide vaccine (ACWY-PS), ACWY-TT shows better antibody persistence in terms of serum bactericidal assay using baby rabbit complement (rSBA) geometric mean titres (GMTs) up to three years following vaccination for serogroups A, W and Y.

The human complement assay (hSBA) for serogroup A is not an appropriate correlate of protection.

Studies in young infants from 2 months of age have now commenced.